Table 1.

Probabilities of RSV-related Health Outcomes and Efficacies of RSV Prophylaxis

VariableBase-case EstimateSource
Efficacy of RSVIG* 0.483, 8
Efficacy of palivizumab0.5512
Probability of death, if hospitalized for RSV, 0.0123, 8, 12
Probability of hospitalization for RSV (without prophylaxis)13
Gestation
(weeks)
Length of oxygen in the
NICU (days)
Month of NICU
discharge
GroupBase-case
estimate
95% CI
 23–32≥28Sept –NovA0.2460.154 –0.370
Dec –AugB0.1070.063 –0.176
<28Sept –NovC0.0800.046 –0.136
Dec –AugD0.0310.018 –0.055
 33–36≥28Sept –NovE0.1100.050 –0.225
Dec –AugF0.0440.019 –0.096
<28Sept –NovG0.0320.020 –0.052
Dec –AugH0.0120.007 –0.020
  • * The National Institutes of Allergy and Infectious Disease trial showed RSVIG to have an efficacy of 69%. The PREVENT trial demonstrated an efficacy of 41%. When the two studies were pooled, the risk of hospitalization for RSV among observation/placebo subjects was 48/318 (15.1%), and the risk among infants who received RSVIG was 24/308 (7.8%). The combined efficacy, 48%, was used in the base case analysis.3 ,8

  • When the control and intervention arms of the three randomized trials of RSV prophylaxis were pooled, the combined mortality among infants hospitalized for RSV was 1.2% (2/173).3 ,8 ,12

  • In the base-case analysis when considering cost per life-year saved, we assumed that infants who received prophylaxis and were hospitalized for RSV had the same likelihood of death as hospitalized infants who did not receive prophylaxis.